Latest Conference Coverage

Finding New Therapeutic Targets in MS: Daniel Reich, MD, PhD

The senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about further research his lab is conducting into MS mechanisms.

NeuroVoices: Ralph Sacco, MD, MS, on Improving Disparities and Expanding Research in Stroke Care

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed solutions to improve disparities in stroke care and the need for future research on social determinants of health.

Treating Paramagnetic Rim Lesions in Multiple Sclerosis

Jemima Akinsanya, DO, Neuroimmunology Clinical Fellow at the National Institutes of Health, discussed new studies of anakinra and tolebrutinib in MS.

Potential Use of DISCO-MS Survey: Anne Kever, PhD

Understanding Mechanisms of MS Chronic Inflammation: Jemima Akinsanya, DO, and Daniel Reich, MD, PhD

The duo from the National Institutes of Health discussed how monitoring and treating paramagnetic rim lesions can improve patient care in multiple sclerosis.

Need for Research on Social Determinants of Health for Stroke Outcomes: Ralph Sacco, MD, MS, FAAN, FAHA

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed the reasons behind the lack of research on social determinants of health on stroke outcomes.

Improving Racial and Ethnic Disparities in Stroke Care: Ralph Sacco, MD, MS, FAAN, FAHA

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine provided plans of action to reduce racial and ethnic disparities in stroke.

Chariot MS Study of Off-Label Cladribine in Advanced MS: Kimberly Allen-Philbey

The PhD candidate at the Barts MS Center in London discussed the upcoming Chariot MS study as well as further research she would like to conduct in personalized cladribine dosing.

Ways to Lower Genetic Leukodystrophies Misdiagnosis in Clinical Settings: Alise Carlson, MD

Alise Carlson, MD, a resident at Cleveland Clinic, provided insight on how raising awareness for genetic leukodystrophies may ultimately improve misdiagnosis rates.

PF-06939926 Continues to Show Safety and Efficacy in Duchenne Muscular Dystrophy

An update on the phase 1b study of Pfizer’s investigational DMD treatment was presented at the MDA 2021 conference.

Variety of Stroke Data Presented at ISC 2021: Ralph Sacco, MD, MS, FAAN, FAHA

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed a number of presentations from ISC 2021.

IV Edaravone Reduces Chance of Death, Tracheostomy, PAV, and Hospitalization in ALS

Researchers conducted a post-hoc analysis of Study 19 to determine hazard ratios of milestone occurrences in amyotrophic lateral sclerosis.

7-Tesla MRI Use in Research: Jemima Akinsanya, DO, and Daniel Reich, MD, PhD

The duo from the National Institutes of Health discussed the advantages of the ultra-high resolution imaging technology in research.

SGT-001 Shows Improvements in Key DMD Measures, Microdystrophin Expression

Preliminary results from the IGNITE-DMD trial also showed a decreased in creatine kinase levels and improvements on NSAA and PODCI.

Expanding Research on MS Diagnosis Disclosure and Long-Term Impacts: Anne Kever, PhD

The postdoctoral researcher at Columbia University discussed the long-term plans to gain a better understanding of MS diagnosis disclosure and how it can impact other qualities of life.

NeuroVoices: Ralph Sacco, MD, MS, on Florida Stroke Registry, Advancing Stroke Knowledge

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed the abundance of research from the Florida Stroke Registry presented at ISC 2021.

CNS Demyelination and Autoimmune Neurology: Spencer Hutto, MD

The fellow of autoimmune neurology at Massachusetts General Hospital also discussed concerns of associations between multiple sclerosis and COVID-19.

Off-Label, Personalized Cladribine Dosing: Kimberly Allen-Philbey

The PhD candidate at the Barts MS Center in London discussed her study presented at ACTRIMS Forum 2021 that evaluated CPD in patients with relapsing MS.

AT-GAA More Efficacious than Alglucosidase Alfa in Late-Onset Pompe Disease

Researchers observed improvements in motor and respiratory function and biomarkers in the investigational treatment group.

Understanding the Complex Diagnosis of Genetic Leukodystrophies: Alise Carlson, MD

Alise Carlson, MD, a resident at Cleveland Clinic, detailed the reasons for her study evaluating genetic leukodystrophies and their differences to multiple sclerosis at diagnosis.

Viz LVO Software Accurately Detects LVOs in Real-World Setting

The triage software yielded a sensitivity and specificity of 59.7% and 91.5%, respectively, for all scans in a study including more than 1000.

Racial Disparities in EVT Access, Forced Exercise Impact on Poststroke Patients, EVT Benefits Within 24 Hour Window

Neurology News Network for the week ending March 27, 2021.

Florida Stroke Registry Serves as Trough of Valuable Research: Ralph Sacco, MD, MS, FAAN, FAHA

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine outlined the Florida Stroke Registry and its capabilities.

Vamorolone for Duchenne Muscular Dystrophy Shows Better Safety Profile Than Other Corticosteroids

The VBP-LTE study found no evidence of slowed linear growth, insulin resistance, or osteocalcin decreases.

Tenecteplase Demonstrates Noninferiority to Alteplase in Acute Ischemic Stroke

P values showed evidence of statistical significance at the conventional P <.05 threshold for all assessed non-inferiority margins.

Understanding Chronic Inflammation in MS: Daniel Reich, MD, PhD

The senior investigator at the National Institutes of Neurological Disorders and Stroke outlined studies on anakinra and tolebrutinib as part of a new phase 2a clinical trial paradigm.

Wearable Gait Technology Shows Promise in SMA and DMD

There was very good to excellent level of agreement between the instrumented insoles and the gold-standard reference system.

Studies of Anakinra and Tolebrutinib in MS Paramagnetic Rim Lesions: Jemima Akinsanya, DO

The Neuroimmunology Clinical Fellow at the National Institutes of Health discussed the evaluations of 2 therapies in multiple sclerosis that she is partaking in.

Risdiplam Effective in Sustained Motor Function Improvement in SMA Types 2 and 3

Two-year data from the SUNFISH study were presented at the MDA 2021 Clinical and Scientific Conference.

Steps Needed to Improve MS Diagnosis Disclosure Rates: Anne Kever, PhD

The postdoctoral researcher at Columbia University discussed ways clinicians and patients with multiple sclerosis can take to ease the transition of disclosing their diagnosis.